L
Laurence Collette
Researcher at European Organisation for Research and Treatment of Cancer
Publications - 281
Citations - 37642
Laurence Collette is an academic researcher from European Organisation for Research and Treatment of Cancer. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 78, co-authored 276 publications receiving 33811 citations. Previous affiliations of Laurence Collette include VU University Amsterdam & Université catholique de Louvain.
Papers
More filters
Journal ArticleDOI
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Journal ArticleDOI
Radiothérapie hyperfractionnée et accélérée dans les cancers de la tête et du cou: résultats des essais de l'EORTC et impact sur la pratique clinique
Jean-Claude Horiot,P. Bontemps,A.C. Begg,R. Le Fur,W. Van den Bogaert,M. Bolla,Tan-Dat Nguyen,D. van den Weijngaert,Jacques Bernier,Antoine Lusinchi,D. Stuschke,D. Lopez Torrecilla,B. Jancar,Laurence Collette,M. van Glabbeke,Marianne Pierart +15 more
Journal ArticleDOI
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial.
Yasmin Abu-Ghanem,Johannes V. Van Thienen,Christian U. Blank,Maureen J.B. Aarts,Michael Jewett,Igle J. de Jong,Jean-Baptiste Lattouf,Harm H.E. van Melick,Lori Wood,Peter F.A. Mulders,Sylvie Rottey,John Wagstaff,Patricia J. Zondervan,Thomas Powles,Anouk Neven,Laurence Collette,Bertrand Tombal,Bertrand Tombal,John B. A. G. Haanen,Axel Bex,Axel Bex +20 more
TL;DR: Sunitinib exposure in the immediate surgery or surgery after Sunitiniband Malate in treating patients with metastatic kidney cancer (SURTIME) trial was associated with the overall survival (OS) benefit observed in the deferred CN arm as discussed by the authors.
Journal ArticleDOI
A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer
Walter Fiedler,N. Tchen,J. Bloch,P. Fargeot,Roberto Sorio,Jan B. Vermorken,Laurence Collette,Denis Lacombe,Chris Twelves +8 more
TL;DR: Sabarubicin (MEN-10755), a new synthetic anthracycline analogue, was evaluated for safety and efficacy in a multicentre phase II study in patients with advanced hormone refractory prostate cancer, comparable to results recently observed in taxotere-containing regimens.
Journal ArticleDOI
O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial
Julien Taieb,Josep Tabernero,Enrico Mini,Fabien Subtil,Gunnar Folprecht,Jean-Luc Van Laethem,Josef Thaler,John Bridgewater,Evaristo Sanches,Lone Petersen,Philippe Rougier,Laurence Collette,M. Praet,Cécile Girault,Martina Schneider,Pierre Squifflet,Pierre Laurent-Puig,Eric Van Cutsem,Laurent Bedenne,Côme Lepage +19 more
TL;DR: The primary analysis of this randomized phase III trial has not shown a benefit for adding cetuximab to FOLFOX4 in patients with resected stage III KRAS wt CC.